HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
Reaven
Gerald M
GM
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. greaven@cvmed.stanford.edu
D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D018450:Disease Progression; D019317:Evidence-Based Medicine; D005215:Fasting / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism*; D008954:Models, Biological; D011237:Predictive Value of Tests; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin